Financhill
Sell
33

TAK Quote, Financials, Valuation and Earnings

Last price:
$15.02
Seasonality move :
1.13%
Day range:
$14.58 - $14.80
52-week range:
$12.58 - $15.43
Dividend yield:
4.18%
P/E ratio:
67.83x
P/S ratio:
1.58x
P/B ratio:
1.00x
Volume:
2.5M
Avg. volume:
2.1M
1-year change:
14.37%
Market cap:
$46.2B
Revenue:
$30.1B
EPS (TTM):
$0.22

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
TAK
Takeda Pharmaceutical
$7.6B -- 2.48% -- $17.31
AMGXF
AnGes
-- -- -- -- --
DSNKY
Daiichi Sankyo
-- -- -- -- --
HLOSF
Healios KK
-- -- -- -- --
PPTDF
PeptiDream
-- -- -- -- --
SOLTF
Nxera Pharma
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
TAK
Takeda Pharmaceutical
$14.80 $17.31 $46.2B 67.83x $0.33 4.18% 1.58x
AMGXF
AnGes
$0.36 -- $117.8M -- $0.00 0% 22.97x
DSNKY
Daiichi Sankyo
$27.05 -- $50.6B 26.12x $0.20 1.43% 4.10x
HLOSF
Healios KK
$2.25 -- $228.3M -- $0.00 0% 54.40x
PPTDF
PeptiDream
$13.53 -- $1.8B 16.80x $0.00 0% 5.80x
SOLTF
Nxera Pharma
$5.91 -- $531.3M -- $0.00 0% 2.96x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
TAK
Takeda Pharmaceutical
39.43% -0.250 64.47% 0.45x
AMGXF
AnGes
-- 1.309 -- 1.28x
DSNKY
Daiichi Sankyo
5.88% 0.373 1.52% 1.78x
HLOSF
Healios KK
51.17% -2.492 6.95% 1.11x
PPTDF
PeptiDream
25.74% 0.548 5.48% 4.62x
SOLTF
Nxera Pharma
48.1% 1.902 78.18% 2.83x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
TAK
Takeda Pharmaceutical
$4.4B -$491.4M 0.89% 1.49% -5.41% $854.8M
AMGXF
AnGes
$368.5K -$8.2M -33.92% -33.92% -741.83% --
DSNKY
Daiichi Sankyo
$2.3B $402.6M 16.65% 17.67% 15.46% -$43M
HLOSF
Healios KK
$59K -$4.9M -85.83% -196.15% -1239.47% -$5.1M
PPTDF
PeptiDream
$9.6M -$9M 23.58% 34.1% -29.18% -$69.4M
SOLTF
Nxera Pharma
$33M -$14.4M -4.28% -8.65% -28.7% -$14.8M

Takeda Pharmaceutical vs. Competitors

  • Which has Higher Returns TAK or AMGXF?

    AnGes has a net margin of -9.79% compared to Takeda Pharmaceutical's net margin of -737.34%. Takeda Pharmaceutical's return on equity of 1.49% beat AnGes's return on equity of -33.92%.

    Company Gross Margin Earnings Per Share Invested Capital
    TAK
    Takeda Pharmaceutical
    63.73% -$0.21 $76.5B
    AMGXF
    AnGes
    33.2% -$0.03 $21.5M
  • What do Analysts Say About TAK or AMGXF?

    Takeda Pharmaceutical has a consensus price target of $17.31, signalling upside risk potential of 16.94%. On the other hand AnGes has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than AnGes, analysts believe Takeda Pharmaceutical is more attractive than AnGes.

    Company Buy Ratings Hold Ratings Sell Ratings
    TAK
    Takeda Pharmaceutical
    3 1 0
    AMGXF
    AnGes
    0 0 0
  • Is TAK or AMGXF More Risky?

    Takeda Pharmaceutical has a beta of 0.259, which suggesting that the stock is 74.114% less volatile than S&P 500. In comparison AnGes has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock TAK or AMGXF?

    Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.18%. AnGes offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 280.28% of its earnings as a dividend. AnGes pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TAK or AMGXF?

    Takeda Pharmaceutical quarterly revenues are $6.9B, which are larger than AnGes quarterly revenues of $1.1M. Takeda Pharmaceutical's net income of -$676.5M is lower than AnGes's net income of -$8.2M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 67.83x while AnGes's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.58x versus 22.97x for AnGes. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TAK
    Takeda Pharmaceutical
    1.58x 67.83x $6.9B -$676.5M
    AMGXF
    AnGes
    22.97x -- $1.1M -$8.2M
  • Which has Higher Returns TAK or DSNKY?

    Daiichi Sankyo has a net margin of -9.79% compared to Takeda Pharmaceutical's net margin of 12.77%. Takeda Pharmaceutical's return on equity of 1.49% beat Daiichi Sankyo's return on equity of 17.67%.

    Company Gross Margin Earnings Per Share Invested Capital
    TAK
    Takeda Pharmaceutical
    63.73% -$0.21 $76.5B
    DSNKY
    Daiichi Sankyo
    73.52% $0.21 $11.5B
  • What do Analysts Say About TAK or DSNKY?

    Takeda Pharmaceutical has a consensus price target of $17.31, signalling upside risk potential of 16.94%. On the other hand Daiichi Sankyo has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Daiichi Sankyo, analysts believe Takeda Pharmaceutical is more attractive than Daiichi Sankyo.

    Company Buy Ratings Hold Ratings Sell Ratings
    TAK
    Takeda Pharmaceutical
    3 1 0
    DSNKY
    Daiichi Sankyo
    0 0 0
  • Is TAK or DSNKY More Risky?

    Takeda Pharmaceutical has a beta of 0.259, which suggesting that the stock is 74.114% less volatile than S&P 500. In comparison Daiichi Sankyo has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.459%.

  • Which is a Better Dividend Stock TAK or DSNKY?

    Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.18%. Daiichi Sankyo offers a yield of 1.43% to investors and pays a quarterly dividend of $0.20 per share. Takeda Pharmaceutical pays 280.28% of its earnings as a dividend. Daiichi Sankyo pays out 38.65% of its earnings as a dividend. Daiichi Sankyo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical's is not.

  • Which has Better Financial Ratios TAK or DSNKY?

    Takeda Pharmaceutical quarterly revenues are $6.9B, which are larger than Daiichi Sankyo quarterly revenues of $3.2B. Takeda Pharmaceutical's net income of -$676.5M is lower than Daiichi Sankyo's net income of $406M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 67.83x while Daiichi Sankyo's PE ratio is 26.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.58x versus 4.10x for Daiichi Sankyo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TAK
    Takeda Pharmaceutical
    1.58x 67.83x $6.9B -$676.5M
    DSNKY
    Daiichi Sankyo
    4.10x 26.12x $3.2B $406M
  • Which has Higher Returns TAK or HLOSF?

    Healios KK has a net margin of -9.79% compared to Takeda Pharmaceutical's net margin of -6742.11%. Takeda Pharmaceutical's return on equity of 1.49% beat Healios KK's return on equity of -196.15%.

    Company Gross Margin Earnings Per Share Invested Capital
    TAK
    Takeda Pharmaceutical
    63.73% -$0.21 $76.5B
    HLOSF
    Healios KK
    23.68% -$0.18 $26.9M
  • What do Analysts Say About TAK or HLOSF?

    Takeda Pharmaceutical has a consensus price target of $17.31, signalling upside risk potential of 16.94%. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Healios KK, analysts believe Takeda Pharmaceutical is more attractive than Healios KK.

    Company Buy Ratings Hold Ratings Sell Ratings
    TAK
    Takeda Pharmaceutical
    3 1 0
    HLOSF
    Healios KK
    0 0 0
  • Is TAK or HLOSF More Risky?

    Takeda Pharmaceutical has a beta of 0.259, which suggesting that the stock is 74.114% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock TAK or HLOSF?

    Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.18%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 280.28% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TAK or HLOSF?

    Takeda Pharmaceutical quarterly revenues are $6.9B, which are larger than Healios KK quarterly revenues of $249.2K. Takeda Pharmaceutical's net income of -$676.5M is lower than Healios KK's net income of -$16.8M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 67.83x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.58x versus 54.40x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TAK
    Takeda Pharmaceutical
    1.58x 67.83x $6.9B -$676.5M
    HLOSF
    Healios KK
    54.40x -- $249.2K -$16.8M
  • Which has Higher Returns TAK or PPTDF?

    PeptiDream has a net margin of -9.79% compared to Takeda Pharmaceutical's net margin of -24.41%. Takeda Pharmaceutical's return on equity of 1.49% beat PeptiDream's return on equity of 34.1%.

    Company Gross Margin Earnings Per Share Invested Capital
    TAK
    Takeda Pharmaceutical
    63.73% -$0.21 $76.5B
    PPTDF
    PeptiDream
    34.69% -$0.05 $493M
  • What do Analysts Say About TAK or PPTDF?

    Takeda Pharmaceutical has a consensus price target of $17.31, signalling upside risk potential of 16.94%. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than PeptiDream, analysts believe Takeda Pharmaceutical is more attractive than PeptiDream.

    Company Buy Ratings Hold Ratings Sell Ratings
    TAK
    Takeda Pharmaceutical
    3 1 0
    PPTDF
    PeptiDream
    0 0 0
  • Is TAK or PPTDF More Risky?

    Takeda Pharmaceutical has a beta of 0.259, which suggesting that the stock is 74.114% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.312%.

  • Which is a Better Dividend Stock TAK or PPTDF?

    Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.18%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 280.28% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TAK or PPTDF?

    Takeda Pharmaceutical quarterly revenues are $6.9B, which are larger than PeptiDream quarterly revenues of $27.8M. Takeda Pharmaceutical's net income of -$676.5M is lower than PeptiDream's net income of -$6.8M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 67.83x while PeptiDream's PE ratio is 16.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.58x versus 5.80x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TAK
    Takeda Pharmaceutical
    1.58x 67.83x $6.9B -$676.5M
    PPTDF
    PeptiDream
    5.80x 16.80x $27.8M -$6.8M
  • Which has Higher Returns TAK or SOLTF?

    Nxera Pharma has a net margin of -9.79% compared to Takeda Pharmaceutical's net margin of -11.44%. Takeda Pharmaceutical's return on equity of 1.49% beat Nxera Pharma's return on equity of -8.65%.

    Company Gross Margin Earnings Per Share Invested Capital
    TAK
    Takeda Pharmaceutical
    63.73% -$0.21 $76.5B
    SOLTF
    Nxera Pharma
    75.69% -$0.06 $863.6M
  • What do Analysts Say About TAK or SOLTF?

    Takeda Pharmaceutical has a consensus price target of $17.31, signalling upside risk potential of 16.94%. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Nxera Pharma, analysts believe Takeda Pharmaceutical is more attractive than Nxera Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    TAK
    Takeda Pharmaceutical
    3 1 0
    SOLTF
    Nxera Pharma
    0 0 0
  • Is TAK or SOLTF More Risky?

    Takeda Pharmaceutical has a beta of 0.259, which suggesting that the stock is 74.114% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.648%.

  • Which is a Better Dividend Stock TAK or SOLTF?

    Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.18%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 280.28% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TAK or SOLTF?

    Takeda Pharmaceutical quarterly revenues are $6.9B, which are larger than Nxera Pharma quarterly revenues of $43.6M. Takeda Pharmaceutical's net income of -$676.5M is lower than Nxera Pharma's net income of -$5M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 67.83x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.58x versus 2.96x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TAK
    Takeda Pharmaceutical
    1.58x 67.83x $6.9B -$676.5M
    SOLTF
    Nxera Pharma
    2.96x -- $43.6M -$5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Asana Stock Be in 5 Years?
Where Will Asana Stock Be in 5 Years?

Asana stock hasn’t given many investors on Wall Street any…

Where Will Dell Stock Be in 5 Years?
Where Will Dell Stock Be in 5 Years?

So you’re looking at Dell (NASDAQ: DELL) and wondering, “Is…

Where Will Cameco Stock Be in 5 Years?
Where Will Cameco Stock Be in 5 Years?

Cameco (NYSE: CCJ) isn’t exactly the kind of stock you…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
70
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 47x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
84
SBET alert for May 30

SharpLink Gaming [SBET] is down 3.17% over the past day.

Buy
55
RGC alert for May 30

Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.

Buy
73
CTEV alert for May 30

Claritev [CTEV] is up 7.82% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock